[1] |
吴孟超.原发性肝癌在中国的治疗和研究现状[J].成都医学院学报,2012,(2):161-162.
|
[2] |
Sodani K, Patel A, Kathawala RJ, et al. Multidrug resistance associated proteins in multidrug resistance[J]. Chin J Cancer, 2012, 31(2):58-72.
|
[3] |
Keppler D. Multidrug resistance proteins(MRPs,ABCCs): importance for pathophysiology and drug therapy[J]. Handb Exp Pharmacol, 2011(201):299-323.
|
[4] |
Li Y, Revalde JL, Reid G, et al. Modulatory effects of curcumin on multi-drug resistance-associated protein 5 in pancreatic cancer cells[J]. Cancer Chemother Pharmacol, 2011, 68(3):603-610.
|
[5] |
König J, Hartel M, Nies AT, et al. Expression and localization of human multidrug resistance protein (ABCC) family members in pancreaticcarcinoma[J]. Int J Cancer, 2005, 115(3):359-367.
|
[6] |
Asghar U, Meyer T. Are there opportunities for chemotherapy in the treatment of hepatocellular cancer?[J]. J Hepatol, 2012, 56(3):686-695.
|
[7] |
Chen X, Liu HP, Li M, et al. Advances in non-surgical management of primary liver cancer[J]. World J Gastroenterol, 2014, 20(44):16630-16638.
|
[8] |
Verslype C, Rosmorduc O, Rougier P, et al. Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2012, 23 Suppl 7: vii41-48.
|
[9] |
Murata S, Mine T, Sugihara F, et al. Interventional treatment for unresectable hepatocellular carcinoma[J]. World J Gastroenterol, 2014, 20(37): 13453-13465.
|
[10] |
Petrelli F, Coinu A, Borgonovo K, et al. Oxaliplatin-based chemotherapy: a new option in advanced hepatocellular carcinoma. a systematic review andpooled analysis[J]. Clin Oncol, 2014, 26(8):488-496.
|
[11] |
Abdel-Rahman O. Revisiting oxaliplatin-based regimens for advanced hepatocellular carcinoma[J]. Curr Oncol Rep, 2014, 16(8):394.
|
[12] |
Qin S, Bai Y, Lim H Y, et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin aspalliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia[J]. J Clin Oncol, 2013, 31(28):3501-3508.
|
[13] |
Tiwari AK, Sodani K, Dai CL, et al. Revisiting the ABCs of multidrug resistance in cancer chemotherapy[J]. Curr Pharm Biotechnol, 2011, 12(4):570-594.
|
[14] |
张慧,符立梧.多药耐药相关蛋白及其在肿瘤耐药中的作用[J].药学学报,2011,46(5): 479-486.
|
[15] |
Adema AD, Floor K, Smid K, et al. Overexpression of MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the nucleoside analogs cytarabineand troxacitabine, but not gemcitabine[J]. Springerplus, 2014(3): 732.
|
[16] |
冷中斌,褚忠华,赵海燕,等.原发性肝癌多药耐药基因的表达与化疗敏感预测的相关性研究[J].岭南现代临床外科,2008,8(3):177-180.
|
[17] |
张华耀,刘建平,苏正,等.多药耐药相关蛋白4在肝癌细胞株SMMC-7721中化疗耐药的作用[J].中华实验外科杂志,2015,32(3):502-504.
|
[18] |
Wijnholds J, Mol CA, van Deemter L, et al. Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs [J]. Proc Natl Acad Sci U S A, 2000, 97(13):7476-7481.
|
[19] |
Nambaru PK, Hübner T, Köck K, et al. Drug efflux transporter multidrug resistance-associated protein 5 affects sensitivity of pancreatic cancer celllines to the nucleoside anticancer drug 5-fluorouracil[J]. Drug Metab Dispos, 2011, 39(1):132-139.
|